Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Public ClinicalTrials.gov record NCT04670445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer. The intervention is an educational video and question prompt list (QPL) to promote communication between patients, caregivers, and the oncology team about the risks and benefits of immunotherapy.
Study identification
- NCT ID
- NCT04670445
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 199 participants
Conditions and interventions
Conditions
- Stage IV Melanoma
- Advanced Lung Cancer
- Stage IV Non-Small Cell Lung Cancer
- Unresectable Non-Small Cell Lung Carcinoma
- Unresectable Stage III Non-Small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Stage IV Merkel Cell Carcinoma
- Stage IV Cutaneous Squamous Cell Carcinoma
- Stage IV Basal Cell Carcinoma
- Stage IV Breast Cancer
- Stage IV Colorectal Cancer
- Stage IV Gastric Cancer
- Stage IV Esophageal Cancer
- Stage IV Hepatocellular Cancer
- Stage IV Renal Cell Carcinoma
- Stage IV Bladder Cancer
- Stage IV Head and Neck Squamous Cell Carcinoma
- Stage IV Cervical Cancer
- Stage IV Endometrial Cancer
- Stage IV Mesothelioma
- Immunotherapy
- Immune Checkpoint Inhibitors
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2021
- Primary completion
- Mar 22, 2023
- Completion
- Mar 31, 2024
- Last update posted
- Aug 24, 2026
2021 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04670445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04670445 live on ClinicalTrials.gov.